Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α

BACKGROUND: In a randomised phase III trial of treatment-naive patients with metastatic renal cell carcinoma, sunitinib showed significant improvement in progression-free survival (PFS) compared with interferon (IFN)-α. We assessed between-treatment differences in overall benefit using a quality-adj...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Patil, S, Figlin, R A, Hutson, T E, Michaelson, M D, Negrier, S, Kim, S T, Huang, X, Motzer, R J
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2012
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3349250/
https://ncbi.nlm.nih.gov/pubmed/22568998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.149
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы